Abstract: High-yield antibiotics producing strain, preparation method and use thereof are provided in the present invention. The high-yield strain is a mutagenized strain derived from Colephoma empetri, and deposited in CGMCC with the accession number of CGMCC 4129. The preparation method comprises the following steps: (a) mixing a seed liquid of Colephoma empetri of Accession No. FERM BP-2635 with nitrosoguanidine to obtain a mixture a; (b) mixing said mixture a with a wall-breaking enzyme to obtain protoplasts; (c) regenerating said protoplasts to obtain single colonies; and (d) culturing said single colonies to obtain said mutagenized strain. The obtained strain has stable genetic and producing property, produces little impurities in fermentation, and is suitable for industrialization.

Abstract: Disclosed are a high purity of caspofungin or salts thereof, and a preparation method thereof, and use thereof. Disclosed are a caspofungin or salts thereof with low solvent residue and hyposaline, and a preparation process comprising: dissolving a crude product of caspofungin or slats thereof into a system of water and acetic acid, them mixing with a first organic solvent ethyl alcohol, subsequently mixing with a second organic solvent ethyl acetate, then being subject to filtration and drying together with water, to obtain caspofungin or salts thereof with high stability, low solvent residue and hyposaline.

Abstract: The method of the preparation of micafungin sodium comprises the step of mixing the weak base and the aqueous solution containing micafungin acid (the structure is illustrated by formula I) or the mixed aqueous solution containing the compound of formula I and organic solvent in order to obtain the sodium salt of micafungin (the structure is illustrated by formula II).

Abstract: The crystalline form A of Bimatoprost of formula I, its preparation method and use are provided. There are characteristic peaks where diffraction angles 2? are 3.2±0.2°, 5.5±0.2°, 11.4±0.2°, 16.7±0.2°, 17.6±0.2°, 19.9±0.2°, 20.8±02° and 22.8±0.2° in the X-ray powder diffraction pattern of the crystalline form A.

Abstract: Provided is a method for preparing a compound represented by Formula I or a salt thereof, wherein Coleophoma empetri F-11899 (FERM BP2635) and/or a mutant strain thereof is cultured in a medium containing amino acid or a salt thereof, an insoluble organic source, and a sugar alcohol, to produce the compound of Formula I or a salt thereof.

Abstract: The present invention provides a liquid medicinal composition containing micafungin or a pharmaceutically acceptable salt thereof and a stabilizing agent.

Abstract: The present invention provides a medicinal composition containing micafungin or a pharmaceutically acceptable salt thereof and trehalose as a stabilizing agent.

Abstract: Disclosed are a caspofungin analog and applications thereof. Said caspofungin analog is a compound having a structure as indicated in Formula (4), or pharmaceutically acceptable slats thereof. R1 can be chosen from hydroxyl, benzyloxy, phenoxy, substituted phenoxy, or substituted benzyloxy. R2, R3, R4, R5 can be chosen from hydrogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, benzyloxyphenyl, substituted benzyloxyphenyl, nitro, fluorine, chlorine, bromine, or iodine. Also disclosed are a preparation method for and applications of said compound.

Abstract: A method for purifying a cyclic lipopepteide or a salt thereof is provided. The method comprises the steps: (1) extracting a fermentation broth containing a compound of formula I or a salt thereof, to obtain an extract 1 after filtration or centrifugation; (2) diluting or concentrating the extract 1 under vacuum to decrease the content of the organic solvent, to obtain an extract 2; (3) loading the extract 2 onto a macroporous absorption resin; (4) washing the macroporpous adsorption resin with water, an organic solvent, or a mixture of water and an organic solvent as a washing solution; and (5) eluting the compound of formula I off from the macroporous adsorption resin with water, an organic solvent, or a mixture of water and an organic solvent as a washing solution as an eluant.

Abstract: A process for purifying cyclic lipopeptide compounds or salts thereof comprising the steps of: (1) charging a crude compound of Formula I onto a macroporous adsorption resin; (2) washing the macroporous adsorption resin using water, an organic solvent or a mixed solution of an organic solvent and water as a washing liquid; and (3) eluting the compound of Formula I from the macroporous adsorption resin using water, an organic solvent or a mixed solution of an organic solvent and water as an eluent. The purification method has the advantages of using a small amount of organic solvents, using no silica gel, and causing little damage to the environment; the purity of the collected compound of formula I is also improved as compared with the methods previously disclosed.

Abstract: Disclosed is a preparation method for caspofungin, comprising the steps: (a) a compound as represented in Formula 2 and a strong leaving group 5 are mixed to obtain a compound as represented in Formula 3; (b) the compound as represented in Formula 3 and ethylenediamine are mixed to obtain a compound as represented in Formula 4; and, (c) the compound as represented in Formula 4 is mixed with a hydroxyl protection agent, and then a borane complex is mixed in to obtain a compound as represented in Formula 1.

Abstract: Disclosed are a caspofungin analog, and a preparation method and applications thereof. The caspofungin analog has a structure as represented in Formula 3.

Abstract: Disclosed is a crystal of carboprost tromethamine as represented by Formula (I). The crystal has characteristic peaks in the X-ray diffraction pattern at the following 2? angles: 6.6±0.2°, 9.9±0.2°, 18.5±0.2° and 20.1±0.2°. Furthermore, also disclosed are preparation method and the use of the crystal.

Abstract: The present invention discloses a crystal of a peptide substance and the preparation method as well as the use thereof. Said crystal B possesses peaks at the following 2? angles in the X-ray diffraction pattern (XRPD): 3.2±0.2°, 5.4±0.2°, 6.2±0.2°, and 9.3±0.2°.

Abstract: High yield antibiotics producing fungus strain, preparation method and use thereof are provided. The fungus strain is a mutant derived from Glarea lozoyensis, and deposited in CGMCC with the accession number of CGMCC 2933. The preparation method concludes following steps: (a) mixing the culture media of Glarea lozoyensis strain ATCC 20957 with nitrosoguanidine, and obtaining mixture a; (b) mixing lywallzyme with the mixture a, and obtaining protoplasts; (c) regenerating the protoplasts, and obtaining single clones; and (d) culturing the single clones, then obtaining the mutant strain. This fungus strain has stable genetic and producing property, produces little impurities in fermentation, and is suitable to be used in industry.

Abstract: The crystalline form A of Bimatoprost of formula I, its preparation method and use are provided. There are characteristic peaks where diffraction angles 2? are 3.2+0.2°, 5.5+0.2°, 11.4+0.2°, 16.7+0.2°, 17.6+0.2°, 19.9+0.2°, 20.8±02° and 22.8+0.2° in the X-ray powder diffraction pattern of the crystalline form A.

Abstract: High yield antibiotics producing fungus strain, preparation method and use thereof are provided. The fungus strain is a mutant derived from Glarea lozoyensis, and deposited in CGMCC with the accession number of CGMCC 2933. The preparation method concludes following steps: (a) mixing the culture media of Glarea lozoyensis strain ATCC 20957 with nitrosoguanidine, and obtaining mixture a; (b) mixing lywallzyme with the mixture a, and obtaining protoplasts; (c) regenerating the protoplasts, and obtaining single clones; and (d) culturing the single clones, then obtaining the mutant strain. This fungus strain has stable genetic and producing property, produces little impurities in fermentation, and is suitable to be used in industry.

Abstract: The present invention disclosed a novel azacyclohexapeptide or pharmaceutically acceptable salts, preparation methods and uses thereof.

Abstract: The invention provides a novel microorganism producing pravastatin sodium, as well as the method for producing pravastatin sodium by using this microorganism. Micropolyspora roseoalba CGMCC 0624 of the invention is highly tolerant to mevastatin sodium, and has a high transformation rate of mevastatin sodium, and can produce pravastatin sodium with a high efficiency and low cost.

Abstract: The invention provides a novel microorganism producing pravastatin sodium, as well as the method for producing pravastatin sodium by using this microorganism. Micropolyspora roseoalba CGMCC 0624 of the invention is highly tolerant to mevastatin sodium, and has a high transformation rate of mevastatin sodium, and can produce pravastatin sodium with a high efficiency and low cost.